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Summary: A new enzymatic method for the determination of bilirubin in serum and plasma by means of a
Hitachi 704 selective analyzer was evaluated. This endpoint method (37 °C) including a sample blank showed
very reliable results. The range of linearity was 0.3 to 437 μιηοΐ/ΐ bilirubin. The within-run imprecision of
three different bilirubin concentrations (n = 16) was 0.37, 0.44 and 0.76% (coefficient of variation). Between-
assay imprecision (n = 15) was 0.51 to 1.76% (coefficient of variation) for five different control materials.
Inaccuracy, determined with 5 control sera (assigned values: 19, 23.9, 90.7, 142.0 and 295.6 μιηοΐ/ΐ bilirubin),
was 0.14 to 4.27%. Recovery rates, determined in two spiked plasma samples, were 97.8% and 99.1%, and
in six bilirubin standard solutions between 92 and 99%. The comparison with the routinely used 2.5-
dichlorophenyl diazonium salt method as well as with the Jendrassik & Gr0/((1938) Biochem. Z. 297, 81 —89)
method as the reference yielded correlation coefficients f r = 0.997 and r = 0.998.
Introduction
For several years, the determination of bilirubin has
been one of the most frequently requested methods
in clinical-chemical laboratories. Since van den Bergh
& Snapper (1) first described the reaction of bilirubin
in human serum with Ehrlich'* di zo reagent, a mul-
titude of bilirubin methods has been published. Cui>
rently, many clinical laboratories use methods based
on those of Jendrassik & Grof (2), or Rand & di
Pasqua, using 2.4-dichlorophenyl diazonium salt (3),
or Wahlefeld et aL, using 2.5-dichlorophenyl diazon-
ium salt (4) as the coupling reagent. In addition,
bilirubin is sometimes determined by direct spectro-
metry (5).
The first enzymatic determination of bilirubin in
serum was reported by Grzesiak & Coleman (6) and
Glick et al. (7). They used bilirubin oxidase (EC
1.3.3.5), isolated and purified from Myrothecium ver-
rucaria MT-1 by Murao & Tanaka (8) some years
before. These authors had already discovered that
oxidation of bilirubin (both conjugated and uncon-
jugated) to biliverdin was catalysed by this enzyme,
followed by a further oxidation of biliverdin to one
or more purple compounds. The reaction sequence in
the assay was:
Bilirubin
Bilirubin + 1/2 O2 oxidase ' Biliverdin + H2O
Biliverdin + O2 > Purple compound(s)
Recently this method has been jointly evaluated by
three laboratories, using both the manual procedure
and an adapted version on the centrifugal analyzer
Cobas-Bio (9). The Jendrassik & Grof method was
used as a reference.
The aim of the present study was to evaluate the
method adapted to a Hitachi 704, using the Jendrassik
& Grof procedure and the routinely used 2.5-dichlo-
rophenyl diazonium salt method for comparison. Pos-
sible interfering substances were investigated.
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Materials and Methods
Materials
For the precision and accuracy studies we used patient plasma
samples (NH4-heparinate) and control sera (Ultimate D, De-
cision 1, Beckman Instruments, M nchen). For calibration of
the 2.5-dichlorophenyl diazonium salt and the Dri-STAT
method the C 8 calibrator (120.2 μπιοΐ/ΐ bilirubin) from Beck-
man Instruments, M nchen, was used. To prepare the plasma
samples for evaluating the recovery rate we used bovine albu-
min-based bilirubin standards (No 7890, Sigma Chemie,
M nchen) dissolved in water to give final concentrations of
85.05 μιηοΙ/1 (solution 1) and 350.6 μιηοΐ/ΐ (solution 2), respec-
tively.
Tab. 1. Instrument settings for the determination of total bili-
rubin (Hitachi 704)
Sample No 1:
1 part plasma (17.7 μπιοΐ/ΐ bilirubin)
solution 1.
-f 4 parts bilirubin
Sample No 2:
1 part plasma (176.0 μπιοΐ/ΐ bilirubin) 4- 9 parts bilirubin
solution 2.
Bilirubin (reference grade) was from Pfanstiehl Laboratories,
Inc., Waukegan, IL 60085. Chemicals of p. a. quality for the
Jendrassik & Grof reagents were from Sigma Chemie, M nchen.
Bovine serum albumin No. 11930 was from Serva, Heidelberg.
Frigen® was from Raab & Karcher, M nchen. The metabolic
substances (reagent grade), ammonium chloride, urea, creatine,
guanidine, guanidinosuccinic acid, uric acid, guanidinoacetic
acid, xanthine, hypoxanthine, adenine, tryptamine, 3-indoxyl-
sulphate (indican) and creatinine were from Sigma Chemie,
M nchen.
To study the influence of hypertriglyceridaemia 10 lipaemic sera
(triacylglycerol concentrations 2.85-12.3 mmol/1) with low bili-
rubin (2.7-5.7 μιηοΐ/l) were split. For moderately elevated
bilirubin values, one half of the samples was spiked with bili-
rubin (average concentration 30 μηιοΐ/ΐ). The samples were then
treated with Frigen® to separate the triacylglycerols according
to Voigt (10). Bilirubin was measured in the samples before and
after the clearing procedure.
Haemolysate was obtained by sonification of four times washed
human erythrocytes followed by centrifugation.
To test metabolites for interference in the assay, the substances
were added to aliquots of pooled human serum to obtain
concentrations a hundred times higher than reference values
found in healthy subjects (11).
Drugs and diagnostics were added to plasma in concentrations
five times of those usually present in patients' sera.
Instruments
The 2.5-dichlorophenyl diazonium salt and the Dri-STAT®
method were performed on a multichannel selective analyzer
(Hitachi 704, Boehringer Mannheim, FRG). The instrument
settings for the Dri-STAT® method are given in table 1. The
Jendrassik & Grof method was performed manually on the
Eppendorf Me platz MKE 5081 (Eppendorf Ger tebau Ham-
burg, FRG).
Reagents
Reagents for the 2.5-dichlorophenyl diazonium salt method
(Bilirubin DPD, No 123951) were from Boehringer Mannheim.
The Dn-STAT®-bilirubin kit was from Beckman Instruments,
M nchen. Reagents and bilirubin standard solutions for the
Jendrassik & Grof method were prepared as described by Dou-
mas et al. (12).
Test
Assay Code
Sample Volume
Rl Volume
R2 Volume
Wavelength
Calib. Method
Std. (1) Conc.-Pos.
Std. (2) Conc.-Pos.
Unit
Sd Limit
Duplicate Limit
Sensitivity Limit
Abs. Limit (Inc/Dec)
Expected Value
Instrument Factor
[EBili]
[2Pomt]:[15]-[32]
[15] · ι
[350] [50] [NO]
[30] [20] [NO]
[415] [546]
[Linear] [0]
[0.0]-[1]
[120.1]-[3]
[μπιοΐ/ΐ]
[0.1]
[100]
[0]
[2000] [Decrease]
[0]-[600]
[1.00]
Methods
The Dri-STAT® method was performed according to the man-
ufacturer's instructions, and the Jendrassik & Grof procedure,
used as the reference method, was performed according to
Doumas et al. (12, 13). The 2.5-dichlorophenyl diazonium salt
method was also used for comparison, and was performed
according to the manufacturer's instructions, except that the
C8 calibrator (see 'materials') was employed.
Statistics
For statistical analysis of the paired samples in the method's
comparison and of the method's linear range, a nonparametric
procedure was employed (14). The calculations were performed
on a desk top computer HP 217. For testing the influence of
hypertriglyceridaemia on matched pairs, the Wilcoxon signed
rank test (15) was used.
Results
Linearity
To study the linearity range, aliquots of a pool plasma
were spiked with albumin-based bilirubin solutions of
increasing bilirubin concentrations. Each dilution was
determined in duplicate. We obtained linearity within
the range of 0.3-437 μιηοΐ/ΐ bilirubin (fig. 1). The
cusum-test showed no significant deviation from lin-
earity. The coefficient of variation was r = 0.9999.
Precision
The determination of the within-run precision was
performed in three concentration ranges with low,
medium and high bilirubin values, resulting in coef-
ficients of variation between 0.37 — 0.76% (tab. 2).
The between-run precision determined in four control
sera over a period of 15 days resulted in coefficients
of variation (CV %) between 0.51-1.76% (tab. 3).
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Tab. 4. Accuracy of the Dri-STAT® method, given as the av-
erage relative deviation from the assigned value
0 50 100 150 200 250 300 350 400 450
Bilirubin (expected) Ejjmol/l]
Fig. 1. Linearity of the bilirubin determination in plasma up
to 437 μιηοΐ/ΐ bilirubin.
x-axis: expected value,
y-axis: measured value,
equation of the line:
y = --2.4 + 1.026X,
correlation coefficient r = 0.9999.
Tab. 2. Within-run precision. Human pooled plasma at three
different bilirubin concentrations
Material
Plasma 1
Plasma 2
Plasma 3
n
16
16
16
x
[μιηοΐ/ΐ]
17.04
133.21
249.30
s
Dimol/1]
0.13
0.59
0.93
CV
[%]
0.76
0.44
0.37
Tab. 3. Between-run precision. Control materials at five differ-
ent bilirubin concentrations
Material x s CV
[μιηοΐ/ΐ] [μπιοΐ/ΐ] [%]
Ultimate D,
Level 1
Level 2
Level 3
Level 4
Decision 1
15
15
15
15
15
22.88
89.86
141.8
289.6
18.37
0.404
0.476
0.730
2.156
0:228
1.76
0.53
0.51
0.72
1.24
Accuracy
The accuracy of the method was checked by means
of assaying control sera, and by recovery of spiked
plasma samples as well as of 6 bilirubin standard
solutions (see 'reagents'), and by method compari-
sons. After a period of 15 days we obtained very good
coefficients of variation between 0.14 and 4.27%
(tab; 4).
Material
Ultimate D
Level 1
Level 2
Level 3
Level 4
Decision 1
n
15
15
15
15
15
Assigned
mean (x)
[μηιοΐ/ΐ]
23.9
90.7
142.0
295.6
19.0
Found
mean (x)
[μηιοΐ/ΐ]
22.88
89.86
141.8
298.6
18.37
Average
deviation
4.27
0.93
0.14
1.01
3.31
The recovery rates of plasma samples one and two
were 97 and 99%, and of the 6 bilirubin standard
solutions between 92 and 99%. The scatter diagram
of the bilirubin determinations (n = 88) with the ox-
idase method in comparison with the Jendrassik &
Grof method as the reference is given in figure 2. The
equation of the line was y = —1.859 + l.Ollx, the
correlation coefficient r = 0.998. In the additional
comparison of the Dri-STAT® and the 2.5-dichloro-
phenyl diazonium salt method 140 patients' samples,
also representing normal and abnormal test results
were split and bilirubin was determined. A good cor-
relation (r = 0.997) was obtained (fig. 3) and the
equation of the regression line was y = —0.920
+ 0.995x. For the two method comparisons no sig-
.nificant differences from b = 1 were calculated, how-
ever, significant differences from a = 0 do exist for
both the increments of a. The cusum-tests showed no
significant deviation from linearity. The bilirubin ox-
idase method resulted in values about 1 μιηοΐ/ΐ and
2.5 μπιοΐ/l lower than those measured with the Jen-
drassik & Grof and the 2.5-dichlorophenyl diazonium
salt method, respectively.
700
g 600
Ο
3 500
'S
H 400
300
S
CO
200
100
0 100 200 300 400 500 600 700
Bilirubin (Jendross/k & 6rof method) [>jmol/IJ
Fig. 2. Comparison of methods: Jendrassik & Grof(\) and the
Dri-STAT® method (y) N = 88;
equation of the line y = —1.859 -I- l.Ollx
correlation coefficient r = 0.998.
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Ο 100 200 300 400 500 600 700
Bilirubin
(dichlorophenyl diozonium salt method) [^imol/l]
Fig. 3. Comparison of methods: 2.5-dichlorophenyl diazonium
salt (x) and the Dri-STAT® method (y) Ν = 140;
equation of the line y = —0.920 + 0.995x,
correlation-.coefficient r = 0.997.
300r
200
E
I
•i 100
QQ
3000 100 200
Bilirubin (Jendrossik 8 Grof method)
Fig. 4. Bilirubin determined in newborn sera with the Jendras-
sik & Grof(x) and the Dri^STAT® method (y) N = 53;
equation of the line: y = —1.043 + l.OOSx,
correlation coefficient r = 0.998.
Detection limit
In order to ascertain the detection limit a solution of
spectroscopically bilirubin-free bovine serum albumin
(50 g/1) was determined (n = 16). The detection limit
was calculated according to Kaiser (16) and lay at 0.3
μιηοΐ/ΐ bilirubin.
Carryover
To assess carryover three successive aliquots of a
plasma sample with high bilirubin concentration (240
μπιοΐ/ΐ) were followed by three aliquots of a plasma
with low bilirubin (7.3 μιηοΐ/ΐ). This procedure was
repeated ten times. A relative percentage carryover
(carryover coefficient) of 0.042% was calculated ac-
cording to Haeckel (17), and an overall maximal
carryover of 0.2 μιηοΐ/ΐ bilirubin into the sample with
low bilirubin was calculated by the method of Passey
and coworkers (18).
Bilirubin determination in sera from new-
borns and patients with chronic renal failure
We determined bilirubin in sera from 53 newborns
with the Dri-STAT® method in comparison with the
Jendrassik & Grof method. Corresponding results
were obtained over a wide range (fig. 4). The equation
of the straight line was y = -1.043 + l.OOSx, the
correlation coefficient r = 0.998. Significant differ-
ences from b = 1 and a = 0 could not be detected.
The cusum-test showed no significant deviation from
linearity.
Bilirubin was determined in 37 sera from uraemic
patients with chronic renal failure (serum creatinine
in the range of 681 -1432 μπιοΙ/1) with the Dri-STAT®
method in comparison with the Jendrassik & Grof
reference procedure. Additionally the 2.5-dichloro-
phenyl diazonium salt method was used. The calcu-
lated means of the bilirubin determinations obtained
by the Dri-STAT® method, the Jendrassik & Grof,
and the 2.5-dichlorophenyl diazonium salt method
were χ = 11.0 μπιοΐ/ΐ, χ = 13.4 μπιοΙ/1 and x = 27.2
μιηοΐ/l, respectively.
Interferences
We investigated the influences of some metabolites
possibly responsible for the positive bias of the results
from the 2.5-dichlorophenyl diazonium salt method
in uraemic patients, anticoagulants, free haemoglobin,
hypertriglyceridaemia, drugs and diagnostic sub-
stances.
The addition of the 13 metabolic substances afore-
mentioned in 'materials' did not cause any bias of the
bilirubin values obtained with the Dri-STAT®
method. However, the metabolite 3-indoxylsulphate
(indican) markedly increased the bilirubin values of
the 2.5-dichlorophenyl diazonium salt method, re-
sulting in an apparently total bilirubin of about 98
μιηοΐ/ΐ for each 1 mmol/1 of added indican.
The influence of in-vitro anticoagulants and a gly-
colysis inhibitor at concentrations'normally found in
plasma, was studied using aliquots of plasma sample
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containing 12.2 μιηοΐ/ΐ bilitubin. No obvious devia-
tion from this value was caused by EDTA, NH4-
heparinate, sodium citrate (1 part sodium citrate so-
lution + 9 parts plasma sample as well as 1 part
sodium citrate solution + 4 parts plasma sample) or
sodium fluoride.
The addition of haemolysate to two plasma samples
with different bilirubin concentrations caused decreas-
ing bilirubin values dependent on increasing haemo-
globin concentrations (tab. 5). The apparent decrease
of the bilirubin concentrations is less in the sample
with the higher bilirubin value.
Investigation of the influence of hypertriglyceridaemia
showed only slight differences of the results obtained
before and after delipidation with Frigen® in the range
up to 12.3 mmol/1 triacylglycerols (tab. 6). The aver-
age difference after Frigen® treatment was 0.15
namol/1 (= 4.1%) in the samples with low bilirubin
and 1.5 mmol/1 (= 4.6%) with elevated bilirubin.
Tab. 5. Influence of free haemoglobin on the Dri-STAT®
method; CH ^= apparent bilirubin concentration caused
by haemoglobin interference, c0 = bilirubin concentra-
tion without haemoglobin interference
Haemo-
globin
added
Γ_/Π[g/i]
0
0.16
0.20
0.33
0.41
0.90
1.13
1.80
2.25
3.60
4.50
Sample 1
Bilirubin
measured
[μ/1]
23
22.2
22.0
21.8
21.5
21.0
20.4
19.9
19.7
19.1
18.6
£ϋ
CQ
1.0
0.964
0.955
0.945
0.931
0.905
0.873
0.845
0.833
0.796
0.764
Sample 2
Bilirubin
measured
[μηιοΐ/ΐ]
328
325.3
325.1
323.9
321.3
317.1
315.2
306.1
304.5
290.4
281.1
£H
Co
1.0
0.991
0.991
0.987
0.979
0.966
0.951
0.928
0.923
0.871
0.834
Tab. 6. Influence of hypertriglycendaemia on determination of
low and elevated bilirubin concentrations in serum be-
fore (a) and after (b) Frigen®-treatment
Sample
1
2
3
4
5
6
7
8
9
10
Triacyl-
glycerols
[mmol/1]
2.85
3.75
4.95
5.20
5.35
7.15
8.05
9.05
10.05
12.3
Low
[μ/1]
a
3.2
3.4
3.5
3.8
2.9
4.5
3.8
3.3
5.7
2.7
bilirubin
b
3.3
3.0
3.6
4.2
3.2
4.5
3.6
3.7
5.9
3.3
Elevated
[μπιοΐ/ΐ]
a
32.6
31.1
31.3
33.7
31,3
35.2
32.9
29.9
33.5
29.5
bilirubin
b
34.4
33.0
31.0
34.4
30.8
36.2
35.4
32.5
35.4
33.3
The influences of drugs and diagnostics were inves-
tigated using aliquots of a plasma sample with 38
μπιοΐ/ΐ bilirubin. The following Pharmaceuticals at
the concentrations shown in parentheses (g/1) were
investigated:
Ampicillin (2.0),
Flucloxacillin (5.0),
Vancomycin (0.5),
Doxycyclin (0.1),
Piperacillin (10.0),
Cefuroxim 750 (0.75),
Gentamicin (0.2),
Imipenem (0.5),
Amikacin (1.0),
Tobramicin (0.2),
Dextran 40 10% (50.0),
lopamidol (41.0),
iotalaminic acid 70 (14.0),
ioxaglinic acid (12.0),
sodium iopodate (3.0) and
acetylosalicylic acid (0.5).
No obvious influence on the bilirubin oxidase method
could be detected.
Discussion
In clinical-chemical laboratories, enzymatic methods
for substrate determination are often used, because
they are specific and, in most cases, easy to handle,
e.g. the determinations of glucose, ammonia, urea
and creatinine.
Recently a new enzymatic method for the determi-
nation of bilirubin in serum or plasma has been de-
scribed based on the oxidation of bilirubin by bili-
rubin oxidase (EC 1.3.3.5) (6, 7).
The results presented in our study confirm the pre-
viously published findings of the above mentioned
group (9) and demonstrate an even better analytical
accuracy.
The superior precision in different ranges and the lack
of carryover can certainly also be ascribed to the
pipetting system and the washing and drying proce-
dure of the Hitachi 704. The results of the within-run
as well as the between-run imprecision are very sat-
isfactory. With respect to accuracy, assessed by meas-
uring control sera, and the recovery of spiked plasma
samples as well s of bilirubin standard solutions, and
by method comparisons, the bilirubin oxidase method
fulfils the usual analytical and clinical requirements
very adequately.
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As the comparison with the Jendrassik & Grof 'method
points out, a good correlation (r = 0.998) exists, and
the mean of concentrations measured enzymatically
is only about 1 μηιοΐ/ΐ lower. Hence we can confirm
the correlation results ofLadouceur et al. (19, 20) who
calculated a slope of b = 0.988, an intercept of
a = —0.150 and a correlation coefficient of
r = 0.991.
With view to the accuracy of the bilirubin oxidase
method, the question arises as to whether the four
fractions (α-δ) of total bilirubin, especially the so-
called δ-fraction, are completely determined in the
course of various hepatobiliary diseases.
To begin with, the good accuracy of the Jendrassik &
Gr /method, which we used as the reference, has been
proved several times. In an extended study the serum
bilirubin of adult patients with hyperbilirubinaemia
was investigated by Weiss et al. (21), using HPLC for
the four separate fractions, and the Jendrassik & Grof
method for total bilirubin. In a similar study using
the same two methods, total bilirubin and its fractions
were determined in sera from paediatric patients (22).
Lauff et al. (23) ascertained a good correlation of
total bilirubin values by the Jendrassik & Grof pro-
cedure with those of a HPLC method. The latter
authors found that the δ-fraction can account for up
to 0.92 of the total bilirubin in pathological sera, so
erroneous results may be obtained in the spectropho-
tometric assay for direct but not total bilirubin. In
this context it must be mentioned that similar bilirubin
values can be obtained by HPLC and the Jendrassik
& Grof method, only if the optimal reaction condi-
tions for the Jendrassik & Grof procedure are used,
as pointed out recently (12, 24). From all these find-
ings the conclusion can be drawn that the Jendrassik
& Grof method, as proposed by Doumas et al. (12),
is well suited for measuring total bilirubin accurately,
regardless of subcomponent composition. Regarding
the excellent correlation of the bilirubin oxidase
method with the Jendrassik & Gro/method, we believe
the new enzymatic method to be a very reliable pro-
cedure.
Furthermore, the method is suitable for measuring
bilirubin in newborn sera over a wide range, and it
performs as well as the Jendrassik & Grof method
(r = 0.998, b = 1.005, a =-1.043). This circum-
stance might be of great interest for paediatric hos-
pitals, because the method needs a sample volume of
only 15 μΐ, and the decision range for application of
phototherapy or exchange transfusion is clearly in-
cluded by the linearity range, which extends to 437
μιηοΐ/ΐ bilirubin.
Depending on the analytical method, haemolysis in-
terferes to a greater or lesser extent with the spectro-
photometric determination of bilirubin. Hitherto, the
procedure least subject to interference by haemolysis
has been the Jendrassik & Grof procedure, published
as the reference method by Doumas et al. (12); addi-
tion of 2.5 g/1 haemoglobin to a serum sample con-
taining 171 μπιοΐ/ΐ bilirubin caused an apparent de-
crease in bilirubin of less than 2%; when ascorbic
acid was present in the reaction mixture no decrease
was observed. Other commercially available modifi-
cations of the Jendrassik & Grof method as well as
the various dichlorophenyl diazonium salt procedures
are influenced by free haemoglobin. After the addition
of 2.5 g/1 free haemoglobin to a serum sample con-
taining 71 μιηοΐ/ΐ bilirubin, van der Woerd et al. (25)
found an apparent decrease in the bilirubiri concen-
tration of 35% by the 2.5^-dichlorophenyl diazonium
salt method, and about 12% by the Jendrassik & Grof
method. From the results in table 5, a serum bilirubin
value of 71 μπιοΐ/ΐ determined with the Dri-STAT®
method will be decreased by about 15%, if 2.5 g/1
free haemoglobin are added. The apparent decrease
of bilirubin is directly related to the amount of free
haemoglobin and dependent on the bilirubin concen-
tration (9), as confirmed in the present study (tab. 5),
i. e. low bilirubin values are more influenced than high
values.
These findings have a bearing on the determination
of bilirubin in newborn sera by means of the Dri-
STAT® method. Meites & Lin (26) measured hae^
molysis in samples from 417 children, of whom 176
were less than 14 days old. They found a mean value
of 0.4 g/1 haemoglobin for the newborns (0 — 13 days);
73% of these values were below 0.5 g/1, whereas less
than 5% were above 1 g/1. The highest value seen was
1.47 g/1. Taking these findings into consideration to-
gether with our results in table 5, one can expect an
apparent bilirubin decrease of 2—6% in the range of
250 — 330 μιηοΐ/ΐ serum bilirubin, if the serum also
contains 0.4—1 g/1 haemoglobin.
Falsely positive bilirubin values determined with the
2.5-dichlorophenyl diazonium salt method in sera
from patients with chronic renal failure are well
known and have also been described for the 2.4-
dichlorophenyl diazonium salt method (27, 28). The
only metabolite found until now in uraemic sera,
interfering with the dichlorophenyl diazonium salt
methods, is indican. In contrast, the accuracy of the
bilirubin oxidase method remained unaffected, as con-
firmed by our results with the Jendrassik & Grof
method, which has previously beoii shown to be free
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from interference by indican (27). Other possible
sources of interference had no effect on the bilirubin
oxidase method.
The influence of hypertriglyceridaemia (up to 12
mmol/1) on the enzymatic bilirubin determination is
very small, so that from a practical point of view a
clearing treatment is unnecessary, although the dif-
ference between the matched pairs with elevated bil-
irubin was statistically significant. The high dilution
of the small volume in the Hitachi 704 might be the
reason for the slight interference.
In conclusion, the bilirubin oxidase method can be
recommended for application in clinical-chemical lab-
oratories.
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